Effect of sunitinib, as first-line chemotherapy, on PD-1 and PD-L1 expression in primary metastatic clear cell renal cell carcinoma

Trial Profile

Effect of sunitinib, as first-line chemotherapy, on PD-1 and PD-L1 expression in primary metastatic clear cell renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Clear cell sarcoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top